Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please ...

Sulfonylureas are often added to metformin to improve glycemic control, but at the known risk of increasing hypoglycemia and weight gain. In a report published in the Lancet, more than 1,500 patients ...

"I think these are very interesting findings, even if the study wasn't powered for cardiovascular end points," said lead investigator Dr Baptist Gallwitz (Eberhard-Karls-University Tübingen, Germany).

Heart Failure Linked to Loss of Cerebral Gray Matter The dipeptidyl peptidase-4 inhibitor linagliptin is noninferior to the sulphonylurea glimepiride for second-line glycemic control and is associated ...

San Diego, CA - Linagliptin (Tradjenta, Boehringer Ingelheim) shows similar efficacy to glimepiride (Amaryl, Sanofi-Aventis) for the treatment of patients with type 2 diabetes, in terms of controlling ...

Clinicians are responsible for selecting a suitable second-line treatment for patients with type 2 diabetes mellitus when metformin monotherapy fails. New evidence could aid clinicians in deciding ...

Please provide your email address to receive an email when new articles are posted on . Adults with type 2 diabetes experienced no difference in cardiovascular autonomic neuropathy measures or B-type ...

The Government Analyst, Food and Drug Department, Ministry of Health is advising health care providers and consumers that diabetes medications Metformin and Glimepiride as separate drugs are not being ...

New Delhi : Mascot Health Series Pvt.Ltd has received the Drug Controller General of India’s (DCGI) approval for its triple combination diabetes treatment. Mascot claims to be the first CDMO to launch ...

The head-to-head comparison of four classes of medications assessed multiple metabolic, cardiovascular (CV), and safety outcomes for sulfonylurea glimepiride (Amaryl), the DPP-4 inhibitor sitagliptin ...